Biopharmaceutical/Oncology - Urothelial Cancer Therapeutics
Strategic Profile
UroGen's RTGel platform is a proprietary sustained-release hydrogel technology designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option. The company recently secured a revised $250 million loan agreement with Pharmakon Advisors (signed February 26), providing $200 million to refinance existing debt and fund operations, with an additional $50 million available upon conditions.
Cyborg Score Rationale
The company generated $96.52 million in trailing twelve-month revenue with an 87.95% gross margin, but exhibits a deeply negative net margin of -170.59%. Financial health is under scrutiny with concerning debt-to-equity ratio of -1.11 and an Altman Z-Score of -6.3 placing the company in distress, though sustained revenue generation and pipeline catalysts provide upside optionality.
Top Insights
UGN-102 New Drug Application under FDA review with PDUFA target action date of June 13, 2025, and an ODAC meeting scheduled for May 21, 2025.
The Phase 3 ENVISION trial demonstrated an 18-month duration of response of 80.6% for patients achieving complete response with UGN-102.
Secured $250 million non-dilutive financing in February 2026, addressing near-term liquidity runway and providing operational flexibility.
JELMYTO generated $25.2 million in net product revenue in Q3 2024, demonstrating successful commercialization of approved product.
Named Competitors
KEYTRUDA (pembrolizumab) — Immunotherapy for bladder cancer treatment
VALRUBICIN — Intravesical chemotherapy for bladder cancer
BCG therapy alternatives — Traditional immunotherapy for non-muscle invasive bladder cancer
Recent Developments
(February 2026) Amended $250 million loan agreement with Pharmakon Advisors securing non-dilutive capital
(January 2026) Permanent J Code for ZUSDURI now in effect, expanding patient access to bladder cancer therapy
(June 2025) Expected FDA decision on UGN-102 NDA with May ODAC meeting
Open the full interactive UroGen Pharma Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.